SM-130686

SM-130686
Clinical data
ATC code	none;
Identifiers
	IUPAC name (+)-(3S)-3-(2-chlorophenyl)-1-[2-(diethylamino)ethyl]-3-hydroxo-2-oxo-4-(trifluoromethyl)indoline-6-carboxamide;
CAS Number	259666-71-2 ;
PubChem CID	9890863;
ChemSpider	7980503 ;
UNII	1GH34I6261;
Chemical and physical data
Formula	C22H23ClF3N3O3
Molar mass	469.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c3c1c(cc(c3)C(N)=O)N(CCN(CC)CC)C(=O)C1(O)c2ccccc2Cl;
	InChI InChI=1S/C22H23ClF3N3O3/c1-3-28(4-2)9-10-29-17-12-13(19(27)30)11-15(22(24,25)26)18(17)21(32,20(29)31)14-7-5-6-8-16(14)23/h5-8,11-12,32H,3-4,9-10H2,1-2H3,(H2,27,30)/t21-/m1/s1; Key:YSSPGXCFFITNCE-OAQYLSRUSA-N;
	(verify)

SM-130686 is a small-molecule drug which acts as a potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue,^[1] with around half the potency of the endogenous agonist ghrelin as a stimulator of growth hormone release.^[2]^[3] It produces dose-dependent increases in muscle mass and decrease in body fat, and is under investigation for the treatment of growth hormone deficiency and other medical conditions.^[4] Concerns about its potential use as a performance-enhancing drug for athletes have led to the development of urine tests for SM-130686 and other GHSR agonists, even though no drugs from this class have yet progressed to clinical use.^[5]